A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (Illuminate 101)

Trial Profile

A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (Illuminate 101)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs IMO 2125 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms illuminate 101
  • Sponsors Idera Pharmaceuticals
  • Most Recent Events

    • 05 Jan 2018 According to an Idera Pharmaceuticals media release, Completed enrollment in first cohort and andvanced enrollment in second cohort.
    • 25 Sep 2017 Planned number of patients changed from 40 to 75.
    • 12 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top